Mirae Asset Global Investments
ORIC icon

Mirae Asset Global Investments’s Oric Pharmaceuticals ORIC Stock Holding History

Mirae Asset Global Investments’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.1K Sell
4,630
-605
-12% -$5.49K ﹤0.01% 1353
2026
Q1 		$66.3K Buy
5,235
+503
+11% +$5.71K ﹤0.01% 1244
2025
Q4 		$38.7K Buy
4,732
+977
+26% +$11.2K ﹤0.01% 1446
2025
Q3 		$45.1K Buy
3,755
+1,009
+37% +$10.6K ﹤0.01% 1362
2025
Q2 		$27.9K Buy
2,746
+369
+16% +$2.48K ﹤0.01% 1351
2025
Q1 		$14.6K Buy
2,377
+25
+1% +$219 ﹤0.01% 1426
2024
Q4 		$19.4K Sell
2,352
-199
-8% -$1.83K ﹤0.01% 1427
2024
Q3 		$27.2K Buy
2,551
+538
+27% +$5.32K ﹤0.01% 1393
2024
Q2 		$13.9K Buy
+2,013
New +$18K ﹤0.01% 1431
2024
Q1 		– Sell
-22,043
Closed -$203K – 2591
2023
Q4 		$203K Buy
22,043
+1,362
+7% +$9.85K ﹤0.01% 2334
2023
Q3 		$125K Hold
20,681
– – ﹤0.01% 2418
2023
Q2 		$160K Buy
+20,681
New +$117K ﹤0.01% 2402

Other funds holding ORIC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Mirae Asset Global Investments's ORIC Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Oric Pharmaceuticals (ORIC) stake by 12% in Q2 2026, selling an estimated $5.49K and leaving 4,630 shares worth $50.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1353.

Mirae Asset Global Investments first reported a position in ORIC in Q2 2023 and has held it in 12 quarters since. The position peaked at $203K in Q4 2023. 39 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Mirae Asset Global Investments held 4,630 shares of Oric Pharmaceuticals worth $50.1K as of Q2 2026.
  • Mirae Asset Global Investments sold 605 Oric Pharmaceuticals shares in Q2 2026, an estimated $5.49K.
  • Oric Pharmaceuticals made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1353 holding.
  • Mirae Asset Global Investments first reported a position in Oric Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • Mirae Asset Global Investments's Oric Pharmaceuticals position peaked at $203K in Q4 2023.
  • 39 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.